LMI 1195

Drug Profile

LMI 1195

Alternative Names: 18F LMI 1195; LMI 1195-101; LMI1195; LMI1195 for sympathetic neuronal imaging - Lantheus

Latest Information Update: 13 May 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Lantheus Medical Imaging
  • Class Imaging agents; Radiopharmaceutical diagnostics; Radiopharmaceuticals; Small molecules
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Heart failure

Most Recent Events

  • 13 May 2014 LMI 1195 is still in phase I trials for Heart failure (diagnosis) in USA
  • 29 Mar 2013 LMI 1195 is available for licensing as of 29 Mar 2013. http://www.lantheus.com
  • 07 May 2010 Lantheus Medical Imaging plans a phase II trial for Heart failure (diagnosis) in USA (NCT01085175)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top